Gilder Gagnon Howe & Co’s Audentes Therapeutics, Inc BOLD Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-197,272	Closed	-$11.8M	–	315
2019 Q4	$11.8M	Sell	197,272 -856,266	-81%	-$32.1M	0.12%	129
2019 Q3	$29.6M	Sell	1,053,538 -706,420	-40%	-$24.1M	0.34%	82
2019 Q2	$66.6M	Buy	1,759,958 +140,127	+9%	+$5.38M	0.67%	56
2019 Q1	$63.2M	Buy	1,619,831 +1,459,999	+913%	+$41.9M	0.67%	51
2018 Q4	$3.41M	Buy	+159,832	New	+$4.12M	0.05%	174

Gilder Gagnon Howe & Co's BOLD Position: Q1 2020 in Review

Gilder Gagnon Howe & Co sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 197,272 shares — an estimated $11.8M sold.

Gilder Gagnon Howe & Co first reported a position in BOLD in Q4 2018 and held it in 5 quarters. The position peaked at $66.6M in Q2 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Gilder Gagnon Howe & Co reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 197,272 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $11.8M.
Gilder Gagnon Howe & Co first reported a position in Audentes Therapeutics, Inc in Q4 2018 and held it in 5 quarters.
Gilder Gagnon Howe & Co's Audentes Therapeutics, Inc position peaked at $66.6M in Q2 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2020, filed 15 May 2020.